Duarte Ira, the Chief Financial Officer of Heron Therapeutics, Inc., has reported several significant stock transactions in a recent SEC filing. These transactions, which include acquisitions of both common stock and restricted stock units, highlight a strong commitment to the company's future and may signal strategic moves within the pharmaceutical industry.

Background

Heron Therapeutics, Inc. operates under the SIC classification of Pharmaceutical Preparations. The company is publicly traded and has a CIK of 0000818033. The recent filing on November 3, 2026, details multiple transactions involving Ira's ownership of the company's stock.

What the Filing Says

The filing indicates that on October 30, 2026, Duarte Ira acquired 13,535 shares of common stock and 13,535 restricted stock units (RSUs). Additionally, on October 31, 2026, he acquired another 11,695 shares of common stock and 11,695 RSUs. Following these transactions, Ira now owns a total of 306,051 shares of common stock directly and 175,957 RSUs.

Impact

These transactions may affect shareholders and potential investors by showcasing Ira's confidence in the company's prospects. His role as an officer and the substantial number of shares acquired could influence market perceptions and investor sentiment regarding Heron Therapeutics.

What's Next

The filing does not say what happens next.